BCAX
insider transactionsBicara Therapeutics Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-84.4K
0 buy · 84.4K sell
Net value · 90d
-$1.8M
$0 in · $1.8M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
11
0 buy · 84.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
19.5K sh
Own New
-
Grant·A
Director
$0
19.5K sh
Own New
-
Grant·A
Director
$0
19.5K sh
Own New
-
Grant·A
Director
$0
19.5K sh
Own New
-
Grant·A
Director
$0
19.5K sh
Own New
-
Grant·A
Director
$0
19.5K sh
Own New
-
Grant·A
Director, 10% Owner
$0
19.5K sh
Own New
-
Exercise·M
Ivan Hyep KEY
Chief Financial Officer · 10b5-1
$0
9.2K sh
Own +15%
-
Sell·S
Ivan Hyep KEY
Chief Financial Officer · 10b5-1
$187.9K
9.2K sh · $20.42
Own -6%
-
Exercise·M
Ivan Hyep KEY
Chief Financial Officer · 10b5-1
$34.9K
9.2K sh · $3.79
Own +6%
-
Exercise·M
Claire Mazumdar KEY
Chief Executive Officer · 10b5-1
$0
15.0K sh
Own +11%
-
Sell·S
Claire Mazumdar KEY
Chief Executive Officer · 10b5-1
$60.6K
3.0K sh · $20.35
Own -1%
-
Sell·S
Claire Mazumdar KEY
Chief Executive Officer · 10b5-1
$240.0K
12.0K sh · $19.96
Own -3%
-
Exercise·M
Claire Mazumdar KEY
Chief Executive Officer · 10b5-1
$56.8K
15.0K sh · $3.79
Own +4%
-
Exercise·M
Ryan Cohlhepp KEY
President and COO · 10b5-1
$0
8.0K sh
Own +9%
-
Sell·S
Ryan Cohlhepp KEY
President and COO · 10b5-1
$91.3K
4.5K sh · $20.29
Own -2%
-
Sell·S
Ryan Cohlhepp KEY
President and COO · 10b5-1
$162.3K
8.0K sh · $20.29
Own -4%
-
Exercise·M
Ryan Cohlhepp KEY
President and COO · 10b5-1
$30.3K
8.0K sh · $3.79
Own +4%
-
Grant·A
Chief Medical Officer
$0
85.0K sh
Own New
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
5.5K sh
Own +15%
-
Sell·S
Chief Medical Officer · 10b5-1
$125.8K
5.5K sh · $22.88
Own -9%
-
Exercise·M
Chief Medical Officer · 10b5-1
$20.8K
5.5K sh · $3.79
Own +10%
-
Exercise·M
Ivan Hyep KEY
Chief Financial Officer · 10b5-1
$0
9.2K sh
Own +30%
-
Sell·S
Ivan Hyep KEY
Chief Financial Officer · 10b5-1
$211.6K
9.2K sh · $23.00
Own -6%
-
Exercise·M
Ivan Hyep KEY
Chief Financial Officer · 10b5-1
$34.9K
9.2K sh · $3.79
Own +6%
-
Exercise·M
Claire Mazumdar KEY
Chief Executive Officer · 10b5-1
$0
15.0K sh
Own +10%
-
Sell·S
Claire Mazumdar KEY
Chief Executive Officer · 10b5-1
$354.1K
15.0K sh · $23.61
Own -4%
-
Exercise·M
Claire Mazumdar KEY
Chief Executive Officer · 10b5-1
$56.8K
15.0K sh · $3.79
Own +4%
-
Exercise·M
Claire Mazumdar KEY
Chief Executive Officer · 10b5-1
$0
7.1K sh
Own +1%
-
Exercise·M
Claire Mazumdar KEY
Chief Executive Officer · 10b5-1
$0
7.5K sh
Own +6%
-
Exercise·M
Claire Mazumdar KEY
Chief Executive Officer · 10b5-1
$0
8.2K sh
Own +17%
-
Exercise·M
Claire Mazumdar KEY
Chief Executive Officer · 10b5-1
$38.6K
7.1K sh · $5.45
Own +2%
-
Exercise·M
Claire Mazumdar KEY
Chief Executive Officer · 10b5-1
$28.2K
7.5K sh · $3.79
Own +2%
-
Exercise·M
Claire Mazumdar KEY
Chief Executive Officer · 10b5-1
$36.5K
8.2K sh · $4.44
Own +2%
-
Exercise·M
Ryan Cohlhepp KEY
President and COO · 10b5-1
$0
8.0K sh
Own +8%
-
Sell·S
Ryan Cohlhepp KEY
President and COO · 10b5-1
$103.5K
4.5K sh · $23.01
Own -2%
-
Sell·S
Ryan Cohlhepp KEY
President and COO · 10b5-1
$184.1K
8.0K sh · $23.01
Own -4%
-
Exercise·M
Ryan Cohlhepp KEY
President and COO · 10b5-1
$30.3K
8.0K sh · $3.79
Own +4%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
5.5K sh
Own +13%
-
Sell·S
Chief Medical Officer · 10b5-1
$104.2K
5.5K sh · $18.95
Own -9%
-
Exercise·M
Chief Medical Officer · 10b5-1
$20.8K
5.5K sh · $3.79
Own +10%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 9, 2026 | Christopher Bowden | Grant A | 19.5K | $0 |
| Jun 9, 2026 | Kate Haviland | Grant A | 19.5K | $0 |
| Jun 9, 2026 | Kiran Mazumdar-Shaw | Grant A | 19.5K | $0 |
| Jun 9, 2026 | Scott M. Robertson | Grant A | 19.5K | $0 |
| Jun 9, 2026 | Michael Powell | Grant A | 19.5K | $0 |
| Jun 9, 2026 | Jake Simson | Grant A | 19.5K | $0 |
| Jun 9, 2026 | RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah | Grant A | 19.5K | $0 |
| May 21, 2026 | Ivan Hyep KEY 10b5-1 | Exercise M | 9.2K | $0 |
| May 21, 2026 | Ivan Hyep KEY 10b5-1 | Sell S | 9.2K | $187.9K |
| May 21, 2026 | Ivan Hyep KEY 10b5-1 | Exercise M | 9.2K | $34.9K |
| May 18, 2026 | Claire Mazumdar KEY 10b5-1 | Exercise M | 15.0K | $0 |
| May 18, 2026 | Claire Mazumdar KEY 10b5-1 | Sell S | 3.0K | $60.6K |
| May 18, 2026 | Claire Mazumdar KEY 10b5-1 | Sell S | 12.0K | $240.0K |
| May 18, 2026 | Claire Mazumdar KEY 10b5-1 | Exercise M | 15.0K | $56.8K |
| May 15, 2026 | Ryan Cohlhepp KEY 10b5-1 | Exercise M | 8.0K | $0 |
| May 15, 2026 | Ryan Cohlhepp KEY 10b5-1 | Sell S | 4.5K | $91.3K |
| May 15, 2026 | Ryan Cohlhepp KEY 10b5-1 | Sell S | 8.0K | $162.3K |
| May 15, 2026 | Ryan Cohlhepp KEY 10b5-1 | Exercise M | 8.0K | $30.3K |
| May 8, 2026 | William Schelman | Grant A | 85.0K | $0 |
| Apr 27, 2026 | David Raben 10b5-1 | Exercise M | 5.5K | $0 |
| Apr 27, 2026 | David Raben 10b5-1 | Sell S | 5.5K | $125.8K |
| Apr 27, 2026 | David Raben 10b5-1 | Exercise M | 5.5K | $20.8K |
| Apr 21, 2026 | Ivan Hyep KEY 10b5-1 | Exercise M | 9.2K | $0 |
| Apr 21, 2026 | Ivan Hyep KEY 10b5-1 | Sell S | 9.2K | $211.6K |
| Apr 21, 2026 | Ivan Hyep KEY 10b5-1 | Exercise M | 9.2K | $34.9K |
| Apr 20, 2026 | Claire Mazumdar KEY 10b5-1 | Exercise M | 15.0K | $0 |
| Apr 20, 2026 | Claire Mazumdar KEY 10b5-1 | Sell S | 15.0K | $354.1K |
| Apr 20, 2026 | Claire Mazumdar KEY 10b5-1 | Exercise M | 15.0K | $56.8K |
| Apr 16, 2026 | Claire Mazumdar KEY 10b5-1 | Exercise M | 7.1K | $0 |
| Apr 16, 2026 | Claire Mazumdar KEY 10b5-1 | Exercise M | 7.5K | $0 |
| Apr 16, 2026 | Claire Mazumdar KEY 10b5-1 | Exercise M | 8.2K | $0 |
| Apr 16, 2026 | Claire Mazumdar KEY 10b5-1 | Exercise M | 7.1K | $38.6K |
| Apr 16, 2026 | Claire Mazumdar KEY 10b5-1 | Exercise M | 7.5K | $28.2K |
| Apr 16, 2026 | Claire Mazumdar KEY 10b5-1 | Exercise M | 8.2K | $36.5K |
| Apr 15, 2026 | Ryan Cohlhepp KEY 10b5-1 | Exercise M | 8.0K | $0 |
| Apr 15, 2026 | Ryan Cohlhepp KEY 10b5-1 | Sell S | 4.5K | $103.5K |
| Apr 15, 2026 | Ryan Cohlhepp KEY 10b5-1 | Sell S | 8.0K | $184.1K |
| Apr 15, 2026 | Ryan Cohlhepp KEY 10b5-1 | Exercise M | 8.0K | $30.3K |
| Mar 25, 2026 | David Raben 10b5-1 | Exercise M | 5.5K | $0 |
| Mar 25, 2026 | David Raben 10b5-1 | Sell S | 5.5K | $104.2K |
| Mar 25, 2026 | David Raben 10b5-1 | Exercise M | 5.5K | $20.8K |
About BCAX insider trading
This page tracks insider transactions for Bicara Therapeutics Inc. (BCAX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.